Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase II study of two 21‑day gemcitabine + carboplatin schedules in advanced NSCLC
2006-000744-17Phase 2Completed
- Sponsor
- Ghent University Hospital
- Start
- Mar 2006
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gemcitabine and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Ghent University Hospital. Primary endpoints: Hematologic toxicity comparison between schedules, Response rate and 2 more. Started Mar 2006; status: completed.
02
Drugs
gemcitabinecarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-000744-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000744-17.